[1] |
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology, 2012, 142(6):1264-1273.
|
[2] |
Hong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends[J]. Theranostics, 2013, 3(6):377-394.
|
[3] |
Lianidou ES, Mavroudis D, Pantel K. Advances in circulating tumor cells (ACTC): from basic research to clinical practice[J]. Breast Cancer Res, 2013, 15(6): 319.
|
[4] |
张华,李永兴,乐嫣,等.血清GPC3、GP73和AFP联合检测在HCC中的临床价值[J].标记免疫分析与临床,2014,21(2):132-135.
|
[5] |
Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma[J]. Semin Oncol, 2012, 39(4):461-472.
|
[6] |
Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients[J]. Breast Cancer Res, 2009, 11(4):R46.
|
[7] |
Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition[J]. Science, 2013, 339(6119): 580-584.
|
[8] |
马清,陈水平,陈建魁.肝癌患者循环肿瘤细胞的检测及其临床应用研究进展[J].标记免疫分析临床,2014,21(5):599-602,617.
|
[9] |
滕飞,傅志仁.肝细胞肝癌循环肿瘤细胞研究进展及其在肝移植中的应用前景[J/CD].中华移植杂志:电子版,2013,7(3):157-161.
|
[10] |
Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer[J]. Cancer Cell, 2008, 13(2):153-166.
|
[11] |
Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy[J]. Clin Cancer Res, 2011, 17(11):3783-3793.
|
[12] |
Vona G, Estepa L, Béroud C, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer[J]. Hepatology, 2004, 39(3):792-797.
|
[13] |
刘道永,孙冰生,武金才,等.应用滤过富集法检测肝癌患者外周血中肿瘤细胞[J].中华实验外科杂志,2007,24(4):498-499,封3页.
|
[14] |
Jin T, Peng H, Wu H. Clinical value of circulating liver cancer cells for the diagnosis of hepatocellular carcinoma: a meta-analysis[J]. Biomed Rep, 2013, 1(5):731-736.
|
[15] |
Schulze K, Gasch C, Staufer K, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma[J]. Int J Cancer, 2013, 133(9): 2165-2171.
|
[16] |
Wang JH, Wang CC, Hung CH, et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma[J]. J Hepatol, 2012, 56(2):412-418.
|
[17] |
Shi GM, Xu Y, Fan J, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials[J]. J Cancer Res Clin Oncol, 2008, 134(11):1155-1163.
|
[18] |
Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4):1458-1468.
|
[19] |
van de Stolpe A, den Toonder JM. Circulating tumor cells: what is in it for the patient? a vision towards the future[J]. Cancers, 2014, 6(2):1195-1207.
|
[20] |
Colombo F, Baldan F, Mazzucchelli S, et al. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma[J]. PLoS One, 2011, 6(6):e21369.
|
[21] |
Gorges TM, Pantel K. Circulating tumor cells as therapy-related biomarkers in cancer patients[J]. Cancer Immunol Immunother, 2013, 62(5): 931-939.
|
[22] |
Yan J, Fan Z, Wu X, et al. Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model[J]. Cytometry A, 2015, 87(11):1020-1028.
|